STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

Overview

Journal JACC Basic Transl Sci

Date 2021 Jul 5

PMID 34222720

Citations 7

Authors

Valentina Cannone

Mark Ledwidge

Chris Watson

Paul M McKie

John C Burnett Jr

Kenneth McDonald

Affiliations

Soon will be listed here.

Abstract

B-type natriuretic peptide (BNP) possesses blood-pressure-lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.

Citing Articles

Sex-based differences in metabolic protection by the ANP genetic variant rs5068 in the general population.

Ichiki T, Cannone V, Scott C, Iyer S, Sangaralingham S, Bailey K Am J Physiol Heart Circ Physiol. 2023; 325(3):H545-H552.

PMID: 37417873 PMC: 10538992. DOI: 10.1152/ajpheart.00321.2023.

Genetic evidence implicating natriuretic peptide receptor-3 in cardiovascular disease risk: a Mendelian randomization study.

Cronje H, Karhunen V, Hovingh G, Coppieters K, Lagerstedt J, Nyberg M BMC Med. 2023; 21(1):158.

PMID: 37101178 PMC: 10134514. DOI: 10.1186/s12916-023-02867-x.

The Predictive Value of A, B, and C-Type Natriuretic Peptides in People at Risk of Heart Disease: Protocol for a Longitudinal Observational Study.

Prickett T, Pearson J, Troughton R, Kennedy M, Espiner E JMIR Res Protoc. 2023; 12:e37011.

PMID: 36630163 PMC: 9878369. DOI: 10.2196/37011.

Transcriptomics-based network medicine approach identifies metformin as a repurposable drug for atrial fibrillation.

Lal J, Mao C, Zhou Y, Gore-Panter S, Rennison J, Lovano B Cell Rep Med. 2022; 3(10):100749.

PMID: 36223777 PMC: 9588904. DOI: 10.1016/j.xcrm.2022.100749.

Natriuretic peptide pathways in heart failure: further therapeutic possibilities.

Sangaralingham S, Kuhn M, Cannone V, Chen H, Burnett J Cardiovasc Res. 2022; 118(18):3416-3433.

PMID: 36004816 PMC: 9897690. DOI: 10.1093/cvr/cvac125.

References

Musani S, Fox E, Kraja A, Bidulescu A, Lieb W, Lin H . Genome-wide association analysis of plasma B-type natriuretic peptide in blacks: the Jackson Heart Study. Circ Cardiovasc Genet. 2015; 8(1):122-30. PMC: 4426827. DOI: 10.1161/CIRCGENETICS.114.000900. View

Ledwidge M, Gallagher J, Conlon C, Tallon E, OConnell E, Dawkins I . Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013; 310(1):66-74. DOI: 10.1001/jama.2013.7588. View

Ellis K, Newton-Cheh C, Wang T, Frampton C, Doughty R, Whalley G . Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol. 2011; 50(4):695-701. DOI: 10.1016/j.yjmcc.2011.01.010. View

Seidelmann S, Vardeny O, Claggett B, Yu B, Shah A, Ballantyne C . An Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. J Am Heart Assoc. 2017; 6(4). PMC: 5533018. DOI: 10.1161/JAHA.116.005257. View

Everett B, Cook N, Chasman D, Magnone M, Bobadilla M, Rifai N . Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women. Clin Chem. 2013; 59(3):557-65. PMC: 3694412. DOI: 10.1373/clinchem.2012.194167. View

Cataliotti A, Tonne J, Bellavia D, Martin F, Oehler E, Harders G . Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation. 2011; 123(12):1297-305. PMC: 3081597. DOI: 10.1161/CIRCULATIONAHA.110.981720. View

Lanfear D, Stolker J, Marsh S, Rich M, McLeod H . Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther. 2007; 21(1):55-62. DOI: 10.1007/s10557-007-6007-5. View

Ibrahim N, McCarthy C, Shrestha S, Gaggin H, Mukai R, Szymonifka J . Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays. J Am Coll Cardiol. 2019; 73(11):1273-1284. DOI: 10.1016/j.jacc.2018.12.063. View

Bueno A, Showalter A, Wainscott D, Stutsman C, Marin A, Ficorilli J . Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles. J Biol Chem. 2016; 291(20):10700-15. PMC: 4865917. DOI: 10.1074/jbc.M115.696039. View

10.

Maisel A, Mueller C, Adams Jr K, Anker S, Aspromonte N, Cleland J . State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008; 10(9):824-39. DOI: 10.1016/j.ejheart.2008.07.014. View

11.

McGrath M, Kuroski de Bold M, de Bold A . The endocrine function of the heart. Trends Endocrinol Metab. 2005; 16(10):469-77. DOI: 10.1016/j.tem.2005.10.007. View

12.

Takeishi Y, Toriyama S, Takabatake N, Shibata Y, Konta T, Emi M . Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. Biochem Biophys Res Commun. 2007; 362(2):480-4. DOI: 10.1016/j.bbrc.2007.08.028. View

13.

Costello-Boerrigter L, Boerrigter G, Ameenuddin S, Mahoney D, Slusser J, Heublein D . The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays. Mayo Clin Proc. 2011; 86(3):210-8. PMC: 3046941. DOI: 10.4065/mcp.2010.0708. View

14.

Geelhoed B, Borschel C, Niiranen T, Palosaari T, Havulinna A, Fouodo C . Assessment of causality of natriuretic peptides and atrial fibrillation and heart failure: a Mendelian randomization study in the FINRISK cohort. Europace. 2020; 22(10):1463-1469. PMC: 7544535. DOI: 10.1093/europace/euaa158. View

15.

McKie P, Schirger J, Benike S, Harstad L, Slusser J, Hodge D . Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. Eur J Heart Fail. 2016; 18(4):433-41. PMC: 4874857. DOI: 10.1002/ejhf.468. View

16.

Johansson A, Eriksson N, Lindholm D, Varenhorst C, James S, Syvanen A . Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Hum Mol Genet. 2016; 25(7):1447-56. DOI: 10.1093/hmg/ddw012. View

17.

Pfister R, Luben R, Khaw K, Wareham N . Common genetic variants of the natriuretic peptide gene locus are not associated with heart failure risk in participants in the EPIC-Norfolk study. Eur J Heart Fail. 2013; 15(6):624-7. DOI: 10.1093/eurjhf/hft007. View

18.

Arora P, Wu C, Khan A, Bloch D, Davis-Dusenbery B, Ghorbani A . Atrial natriuretic peptide is negatively regulated by microRNA-425. J Clin Invest. 2013; 123(8):3378-82. PMC: 3726159. DOI: 10.1172/JCI67383. View

19.

Pfister R, Sharp S, Luben R, Welsh P, Barroso I, Salomaa V . Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med. 2011; 8(10):e1001112. PMC: 3201934. DOI: 10.1371/journal.pmed.1001112. View

20.

Meirhaeghe A, Sandhu M, McCarthy M, de Groote P, Cottel D, Arveiler D . Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet. 2007; 16(11):1343-50. DOI: 10.1093/hmg/ddm084. View